Literature DB >> 12821361

Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.

John K Chan1, Vera Loizzi, Mark Youssef, Kathryn Osann, Joanne Rutgers, Steven A Vasilev, Michael L Berman.   

Abstract

OBJECTIVE: To evaluate the biological behavior of noninvasive papillary serous carcinoma of the endometrium. METHODS; From 1990 to 2001, all women with noninvasive uterine papillary serous carcinoma (UPSC) at three Southern California hospitals were identified from tumor registry databases. Data for analysis were collected from hospital charts, office records, and tumor registry files.
RESULTS: Of the 100 patients diagnosed with UPSC, 16 had noninvasive lesions. Twelve underwent a comprehensive surgical staging procedure with omental resection. Six of these 12 women were found to have disease beyond the uterine corpus, including 4 with adnexal involvement, 3 with omental disease, 2 with cervical extension, 1 with pelvic lymph node involvement, and 3 with positive washings. Three women were found to have positive cytology and metastases in more than one location. Of the 12 patients, 1 of the 6 with stage IA disease had distant recurrence and 4 of the 6 with stage II-IV disease recurred. Of the remaining 4 patients who underwent a staging procedure without pathologic omental assessment, 1 was found to have cervical extension. In these 4 women, 1 with stage IA disease recurred.
CONCLUSION: The typical patterns of spread and prognostic factors for endometrioid carcinoma of the uterus do not apply to UPSC. In our series, omental assessment was necessary to detect the 25% of patients with stage IVB disease due to omental involvement. Thus, women with noninvasive UPSC should undergo a comprehensive staging procedure including omental sampling to determine the extent of disease.

Entities:  

Mesh:

Year:  2003        PMID: 12821361     DOI: 10.1016/s0090-8258(03)00195-1

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  23 in total

1.  Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma.

Authors:  Brooke A Schlappe; Amy L Weaver; Michaela E McGree; Jennifer Ducie; Ane Gerda Zahl Eriksson; Sean C Dowdy; William A Cliby; Gretchen E Glaser; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2019-11-24       Impact factor: 5.482

2.  Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients.

Authors:  Kyoko Ono; Hiroyuki Hayashi; Masatoshi Tateno; Reiko Tanaka; Rie Suzuki; Yasuyo Maruyama; Yohei Miyagi; Mitsuko Furuya
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  Abdominal wall metastasis of uterine papillary serous carcinoma in a post-menopausal woman: a case report.

Authors:  Jung-Woo Park; Sung-Ook Hwang
Journal:  J Menopausal Med       Date:  2014-04-28

4.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

5.  The role of omentectomy during the surgical staging in patients with clinical stage I endometrioid adenocarcinoma.

Authors:  Jale Metindir; Gülay Bilir Dilek
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-02       Impact factor: 4.553

6.  Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

Authors:  Karim El-Sahwi; Stefania Bellone; Emiliano Cocco; Francesca Casagrande; Marta Bellone; Maysa Abu-Khalaf; Natalia Buza; Fattaneh A Tavassoli; Pei Hui; Dominik Rüttinger; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

7.  Controversies in surgical staging of endometrial cancer.

Authors:  R Seracchioli; S Solfrini; M Mabrouk; C Facchini; N Di Donato; L Manuzzi; L Savelli; S Venturoli
Journal:  Obstet Gynecol Int       Date:  2010-06-23

Review 8.  Uterine papillary serous carcinoma: state of the state.

Authors:  R Wendel Naumann
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

9.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

Authors:  G E Konecny; L Santos; B Winterhoff; M Hatmal; G L Keeney; A Mariani; M Jones; C Neuper; B Thomas; L Muderspach; D Riehle; H-J Wang; S Dowdy; K C Podratz; M F Press
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

10.  Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.

Authors:  E Cocco; S Bellone; K El-Sahwi; M Cargnelutti; F Casagrande; N Buza; F A Tavassoli; E R Siegel; I Visintin; E Ratner; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.